A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211) - Kunz, P; Catalano, P; Nimeiri, H; Fisher, G; Longacre, T; Suarez, C (2018)
ASCO Annual Meeting. Abstract 4004.